The most advanced molecule crizotinib, which targets the receptor tyrosine kinases ALK and c-MET, has been approved by the US Food and Drug Administration for the treatment of patients with ELM4-ALK positive non-small-cell lung carcinoma [33]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.